The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The use of lorlatinib in ALK-positive NSCLC
Tony Mok, MD, Chinese University of Hong Kong, Hong Kong, China, discusses the 7-year follow-up data from the CROWN trial (NCT03052608) of lorlatinib in ALK-positive non-small cell lung cancer (NSCLC) in the context of the ALEX trial (NCT02075840) comparing alectinib with crizotinib in a similar patient population. Prof. Mok also shares insights into how this data can inform clinical decisions, highlighting the unique toxicities of lorlatinib. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
